Echo Therapeutics, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-12-26: Form 8-K; Period of report 2013-12-23; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2013-12-13: Form 8-K; Period of report 2013-12-10; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; Details 1.01.
- 2013-10-15: Form 8-K; Period of report 2013-10-09; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2013-10-03: Form 8-K; Period of report 2013-09-27; Description 1.02 Termination of a Material Definitive Agreement; 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 1.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-12-26 | 8-K | 2013-12-23 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | ecte8kdec262013.htm |
| 2013-12-13 | 8-K | 2013-12-10 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 3.02 The information set forth in Item 1.01 above regarding the Company’s issuance of shares of Common Stock, shares of Series E Preferred Stock and warrants is hereby incorporated into this Item 3.02. 7.01 On December 10, 2013, the Company issued a press release announcing the Agreement and the Securities Purchase Agreements. | ecte8kdec132013.htm |
| 2013-10-15 | 8-K | 2013-10-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective October 9, 2013, Patrick T. Mooney, M.D., Chairman and a member of the Company’s Board of Directors, resigned from his positions as Chairman of the Board and a member of the Board of Directors. | ecte8koct112013.htm |
| 2013-10-03 | 8-K | 2013-09-27 | 1.02 Termination of a Material Definitive Agreement; 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.02 As discussed in Item 5.02 below, Dr. Patrick Mooney’s employment as Chief Executive Officer and President of Echo Therapeutics, Inc. (the “Company”) terminated effective as of September 27, 2013. 2.05 On October 3, 2013, the Company announced that it had made staff reductions comprising approximately 33% of the Company's workforce. 5.02 On September 28, 2013, Patrick T. Mooney, M.D.’s employment as Chief Executive Officer and President terminated effective as of September 27, 2013. 8.01 On October 3, 2013, the Company issued a corporate update regarding Company activities, expected near-term achievements and comments on recent events. | ecte8koct32013.htm |
| 2013-08-29 | 8-K | 2013-08-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 26, 2013, Echo Therapeutics, Inc. (the “Company”) announced that its Chief Executive Officer, President and Chairman of the Board, Dr. Patrick Mooney, is taking an immediate leave of absence. | ecte8kaug292013.htm |
| 2013-08-09 | 8-K | 2013-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2013, Echo Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2013. | echo8k_aug82013.htm |
| 2013-06-28 | 8-K | 2013-06-25 | 8.01 Other Events | 8.01 On June 25, 2013, the Company received a letter from The Nasdaq Stock Market (“NASDAQ”) stating that the Company had regained compliance with NASDAQ’s Marketplace Rule 5450(a)(2) because the bid price of the Company’s common stock closed at or above the required minimum $1.00 per share for twelve consecutive business days. | ecte8k_june252013.htm |
| 2013-06-19 | 8-K | 2013-06-13 | 8.01 Other Events | 8.01 Echo Therapeutics, Inc. (the “Company”) entered into an underwriting agreement dated June 13, 2013 (the “Underwriting Agreement”) with Aegis Capital Corp. as representative of the several underwriters listed on Schedule C to the Underwriting Agreement (collectively, the “Underwriters”), with respect to the issuance and sale in an underwritten public offering (the “Offering”) by the Company of an aggregate of 4,025,000 shares of the Company’s common stock, $0.01 par value (the “Shares”), at a price to the public of $2.70 per Share. | ecte8kjune192013.htm |
| 2013-06-10 | 8-K | 2013-06-10 | 8.01 Other Events | 8.01 On June 10, 2013, Echo Therapeutics, Inc. (the “Company”) issued a press release announcing its submission to the FDA of a pre-submission package for the Symphony® CGM System. | echo8k_june102013.htm |
| 2013-06-07 | 8-K | 2013-06-06 | 8.01 Other Events | 8.01 On June 7, 2013, Echo Therapeutics, Inc. (the “Company”) filed an Amendment to the Company’s Certificate of Incorporation with the Delaware Secretary of State to effect a 1-for-10 reverse stock split of the Company’s common stock, which was effective at approximately 8 a.m. on June 7, 2013. | echo8k_june62013.htm |
| 2013-05-28 | 8-K/A | 2013-05-22 | 5.07 Submission of Matters to a Vote of Security Holders | ecte8kamay282013.htm | |
| 2013-05-23 | 8-K | 2013-05-22 | 5.07 Submission of Matters to a Vote of Security Holders | ecte8kmay222013.htm | |
| 2013-05-10 | 8-K | 2013-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2013, Echo Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2013. | echo8kmay102013.htm |
| 2013-03-22 | 8-K | 2013-03-18 | 2.02 Results of Operations and Financial Condition; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 2.02 On March 18, 2013, the Company issued a press release announcing its financial results for the year ended December 31, 2012. 3.01 On March 19, 2013, the Company received a letter from the Listing Qualifications Department of the NASDAQ Stock Market (“Nasdaq”) informing the Company that because the closing bid price for the Company's common stock listed on Nasdaq was below $1.00 for 30 consecutive business days, the Company does not comply with the minimum closing bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2). | ecte8kmar222013.htm |
| 2013-03-18 | 8-K | 2013-03-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 12, 2013, the Board of Directors of the Company (the “Board”) appointed Robert F. Doman to fill a vacancy on the Board. | echo8k_mar122013.htm |
| 2013-02-04 | 8-K | 2013-01-31 | 8.01 Other Events | 8.01 Echo Therapeutics, Inc. (the “Company”) entered into underwriting agreements dated January 31, 2013 and February 1, 2013 (collectively, the “Underwriting Agreements”) with Aegis Capital Corp. as representative of the several underwriters listed on Schedule C to each Underwriting Agreement (collectively, the “Underwriters”), with respect to the issuance and sale in an underwritten public offering (the “Offering”) by the Company of an aggregate 13,633,333 shares of the Company’s common stock, $0.01 par value (the “Shares”), at a price to the public of $0.75 per Share. | ecte8kfeb12013.htm |